In this edition of the Motley Fool's health-care show Market Checkup, analysts David Williamson and Max Macaluso look at the big pharma companies circling biotech ViroPharma, a cancer drug granted priority review by the FDA, and a serious patent issue that affects fish oil drugmakers GlaxoSmithKline and Amarin.
David Williamson owns shares of Amarin (ADR). Max Macaluso, Ph.D. and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.